WW is not something Id bet the farm on, but it is reminiscent of other highly operationally levered companies in industries that experience sudden and sustained tailwinds like UAN, RIG or (more recently) AAOI
This doesnt seem to work for this very complicated group of patients
However, it provides context on each providers track record for supporting sustained behaviour change
consider calcifediol when faster repletion or persistent SHPT is relevant), avoid mega-bolus dosing, and reserve active VDRAs for clear SHPT indications with careful calciumphosphatePTH monitoringnot as disease-modifying therapy in unselected CKD
Tirzepatide Analog GLP-2TZ Research Peptide research material
April 30, 2026: FDA announced the proposal, finding no clinical need for outsourcing facilities to compound the three substances from bulk drug substances